FDA's Decision on MDMA Therapy and Economic Updates

The chapter covers the FDA's rejection of marketing authorization for psychiatric therapy with MDMA, impacting psychedelic medicine stocks, along with economic indicators like US private sector employment and the ISM Services PMI. It also discusses the scrutiny faced by GameStop investor Keith Gill from the Massachusetts Securities Regulator.